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Background: Cardiopulmonary exercise testing (CPX) is an important clinical assessment in patients with heart
failure (HF). Neuromuscular electrical stimulation (NMES) has shown promise as an approach to improving car-
diopulmonary performance during exercise and thus could improve key CPX measures. The primary aim of the
proposed study is to perform a systematic review andmeta-analysis on the effects of NMES on key CPXmeasures
in HF patients.
Methods: Data sources: A systematic search without date or language restriction was conducted using Medline,
Embase.com, Cochrane Central Register of Controlled Trials and CINAHL, Amedeo and PEDro. Study eligibility
criteria: Randomized controlled trials, with or without crossover strategy, of NMES-based interventions and a
comparison group submitted to usual medical care or exercise. Participants and interventions: Systolic HF
patients; NMES-based interventions using skin electrodes to produce a muscle contraction. Study appraisal and
synthesis methods: Studies were independently rated for quality (The Jadad Scale, PEDro Scale and The Quality
of Research Score Sheet). Net changeswere compared byweightedmean difference and 95% conﬁdence interval.
Heterogeneity among included studies was explored qualitatively and quantitatively. Begg's funnel plots and the
Egger's regression assessed publication bias.
Results: Findings suggest that NMES provides similar gains in CPX performance compared to traditional exercise
or usual treatment.
Conclusions: CPX performance has substantial prognostic and functional importance in the HF population. Our
results suggest that NMES improves CPX performance and thus may be a valuable therapeutic intervention, pos-
itively altering the clinical trajectory of patients with HF.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Prognosis in heart failure (HF) is commonly determined using
cardiopulmonary exercise test (CPX) results with a greater peak oxygen
consumption, oxygen consumption at the anaerobic threshold, peak
workload, and peak heart rate (VO2peak, VO2AT, PW, HRpeak, respec-
tively) being associated with greater survival. Among other things, the081, Village Adalgisa, House 10,
.
nd Ltd. This is an open access article uncombined HF disease process and a sedentary lifestyle lead to skeletal
muscle weakness/atrophy and poorer CPX performance. Thus, skeletal
muscle dysfunction appears to have the capacity to worsen key CPX
measures, with prognostic importance, in patients with HF [1–9].
In fact, the Muscle Hypothesis of Chronic Heart Failure proposed by
Coats et al. highlights the viscous cycle of HF in which skeletal muscle
weakness and myopathy contribute from a proximal position to the
dyspnea and fatigue as well as ventilatory, neurohumoral, and cardio-
vascular abnormalities associated with this condition [10,11]. Thus, im-
proving skeletal muscle strength and endurance certainly improves
functional performance andmay have the potential to improve progno-
sis in HF. However, for a variety of reasons, not all patients with HF are
able to participate in traditional exercise approaches needed to sufﬁ-
ciently increase skeletal muscle strength and endurance.der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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shown to elicit positive skeletal muscle adaptations in patients unable
to participate in traditional aerobic and/or resistance training programs
at an appropriate stimulus [12]. Generally, NMES consists of repeated,
rhythmic stimulation of skeletal muscle in a static state, using skin elec-
trodes, at an intensity that evokes visible muscle contractions. A grow-
ing body of literature has emerged examining the effects of NMES in
patients with HF, demonstrating beneﬁcial effects in several different
domains, including improvements inmuscle strength, exercise capacity,
endothelial and autonomic function [13–23]. Moreover, several system-
atic reviews have suggested that NMES may be an important adjunct
in the rehabilitation of patients with HF [24,25]. However, to our knowl-
edge, no previous systematic review has examined the effects of NMES
on both maximal and sub-maximal CPX prognostic markers, which can
impact on survival, functional status and quality of life [9–11]. Speciﬁ-
cally, this systemic review reports on the effects of NMES compared to
the standard treatment (moderate aerobic exercise or no-exercise con-
trol) on key CPX variables (VO2peak, VO2AT, PW, HRpeak) in HF patients.2. Methods
This meta-analysis was conducted in accordance with the recom-
mendations and criteria as outlined in the Preferred Reporting Items
for Systematic Reviews and Meta-analysis (PRISMA) statement [26]
and registered at PROSPERO (CRD42014009329).
Criteria for considering studies for this review:2.1. Types of studies
Randomized controlled trials, with or without crossover strategy, of
NMES-based interventions, according to Cochrane Review concept [12],
with a comparison group submitted to usual medical care or exercise
training.2.2. Types of participants
The study population comprised adults aged between 50 and 65.
Only those studieswith a diagnosis of systolic HF [based on clinical ﬁnd-
ings and objective indices such as assessment of ejection fraction,
LVEF b 45%, and NYHA (I–IV)] [27].2.3. Types of interventions
An ambulatory or home-basedNMES interventions, with application
of any therapeutic electrical stimulation using surface electrodes to pro-
duce a muscle contraction in both quadriceps muscles, were included.
The comparison group was an ambulatory or home-based moderate
aerobic exercise group or a no-exercise control group as deﬁned by
the study. The exercise group interventions included an aerobic exercise
programwith the following parameters: 1) At least 30 min, 3 times per
week of moderate aerobic exercise training (60–80% of HRpeak, HR at
VO2AT or RPE 13–15). Patientswith pacemaker andmusculoskeletal dis-
orders that could limit exercise tolerance were excluded. Studies that
included resistance exercise alone or combined with aerobic exercise
were also excluded. Lastly, studies providing NMES and exercise simul-
taneously were also excluded.2.4. Types of outcome measures
Outcomemeasures assessed included one or more of the following:
1) VO2peak (mL kg−1 min−1), 2) VO2AT (mL.kg−1.min−1), 3) Peak Heart
Rate (bpm), and/or 4) Peak Workload (watts).2.5. Search methods for identiﬁcation of studies
Potential studies were identiﬁed by a systematic review librarian.
A systematic search was conducted of Medline (Ovid) (1950 —March
2014), Embase.com (1974 — March 2014), Cochrane Central Register
of Controlled Trials and CINAHL (1981 — March 2014) Amedeo
(1997 — March 2014) and PEDro (1929 — March 2014), all of these
without date restriction. The search strategy included a mix of key-
words selected according to the Medical Subject Headings (Mesh) of
the United States National Library of Medicine (NLM) and free text
terms for the key concepts (Intervention + Population) described
above with ﬁlters to limit to Clinical Trial's (Phases I–IV), RCT's and
RS's search. No language or other limitations were imposed. Reference
lists of papers found were scrutinized for new references. All identiﬁed
papers and its methodological quality were assessed independently by
two reviewers (LMTN and LC). Searches of published papers were con-
ducted up until March 2014 and 2013.
2.6. Search terms strategy for interventions
“Electric Stimulation Therapy”[Mesh] OR “Neuromuscular Electrical
Stimulation” OR “Neuromuscular Stimulation” OR “Functional Electri-
cal” OR “Functional Electrical Stimulation” OR “Neuromuscular Electri-
cal Stimulation” OR “Electrical Muscle Stimulation” OR “Electrical
stimulation Muscle”.
2.7. Search terms strategy for population
“Heart Failure”[Mesh] OR “Left-Sided Heart Failure” OR “Left Sided
Heart Failure” OR “Right-Sided Heart Failure” OR “Right Sided Heart
Failure” OR “Congestive Heart Failure” OR “Heart Failure, Congestive”
OR “Heart Decompensation” OR Cardiomegaly [Mesh] OR Cardiomyopa-
thies [Mesh] OR “Heart Enlargement” OR “Enlarged Heart” OR “Cardiac
Hypertrophy” OR “Heart Hypertrophy” OR Cardiomyopathy OR
“Myocardial Diseases” OR “Myocardial Disease” OR Myocardiopathies
OR Myocardiopathy OR “Secondary Cardiomyopathies” OR “Secondary
Cardiomyopathy” OR “Secondary Myocardial Diseases” OR “Secondary
Myocardial Disease” OR “Primary Cardiomyopathies” OR “Primary
Cardiomyopathy” OR “Primary Myocardial Diseases” OR “Primary
Myocardial Disease”.
3. Data collection and analyses
3.1. Study selection
The references identiﬁed by the search strategy were screened by
title and abstract, and clearly, irrelevant studies were discarded. For se-
lection, abstracts had to clearly identify the study design, an appropriate
population, and relevant components of the intervention as described
above. The main outcomes extracted were VO2peak (mL kg−1 min−1),
VO2AT (mL kg−1 min−1), Peak Workload (watts), and Peak Heart Rate
(bpm). The full-text reports of all potentially relevant trialswere obtain-
ed and assessed independently by two review authors (LMTN and LC)
for eligibility based on the deﬁned inclusion criteria. Any disagreements
were resolved by discussion (Fig. 1).
3.2. Data extraction
The data from the papers included in the reviewwere extracted and
input directly into a single data collection form consisting of the primary
source of information (journal article) and included relevant data re-
garding inclusion criteria (study design; participants; interventions in-
cluding type of NMES/exercise, frequency, duration, intensity, and
modality; comparisons; and outcomes), risk of bias (randomization,
blinding, attrition, and control), and results. The data extraction process
was conducted independently by two persons from the same discipline
Fig. 1. Flowchart summary of study selection process.
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consensus. The agreement ratio prior to amending any discrepancies
was assessed using the kappa statistic and was found to be greater
than 0.90. Study authors were contacted to seek clariﬁcation on the is-
sues of reporting or to obtain further outcome details.
3.3. Quality assessment
The risk of bias and study quality of eligible trials was assessed inde-
pendently by 2 reviewers (LMTN and LC). Study quality was performed
using three different scales [28]: The Jadad Scale, PEDro Scale [6,7] and
The Quality of Research Score Sheet (QRSS) [8]. The Jadad scale assesses
the quality of published clinical trials based methods relevant to ran-
dom assignment, double blinding, and the ﬂow of patients considering
7 items. Items were marked as either present (yes/1) or absent (no/0).
The last 2 items are assigned a negative score, achieving the range of
possible scores from0 (bad) to 5 (good) [29]. The PEDro Scale is a check-
list used to measure the quality of reports based on the Delphi list, de-
veloped by Verhagen et al. [30]. The PEDro Scale included eligibilitycriteria (not used to calculate score), random allocation, concealment
of allocation, similarity at baseline, subject blinding, therapist blinding,
assessor blinding, adequacy of follow-up, intention-to-treat analysis,
between-group statistical analysis, and reports of both point estimates
and measures of variability. Items were marked as either present
(yes/1) or absent (no/0), and a score out of 10 was obtained [31]. The
QRSS was ﬁrst used by Smith et al. [32] and included 16 items:
concealed allocation, random sequence generation, patients were
matched according to relevant patient characteristics, blinding of ob-
server(s), blinding of those performing statistical, blinding of patients,
drop-out number description, intercurrent drop-out description,
intention-to-treat analysis, intra/inter-observer reliability, the relevant
measurement instruments were compared statistically with other
instruments measuring, other co-interventions leading to systematic
differences between groups were avoided, adjunctive (medical) inter-
ventions were reported, comparability of patients, predetermined
rehabilitation time and/or number and/or dosage of exercises, actual re-
habilitation time and/or number and/or dosage of exercises. Itemswere
marked as either present (yes/1) or absent (no/0), and a score out of 16
Fig. 2. Forest plotmean, funnel plot of standard error by standard differences inmeans for the comparison of neuromuscular electrical stimulation (NMES) versus exercise for peak oxygen
consumption (VO2peak), oxygen consumption at anaerobic threshold (VO2AT), peak hear rate (HRpeak) and power workload (PW).
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nel plots and Egger's regression test were examined [29] and were con-
sidered adequate when p N 0.05 (Figs. 2 and 3).
3.4. Data analysis
Datawere processed in accordancewith the Cochrane Handbook for
Systematic Reviews of Interventions [30]. The outcomes are presented
as continuous data using the data extracted from eligible studies and in-
cluded themean value of the outcomemeasurements in each interven-
tion and control group (ME and MC), the standard deviation of the
outcome measurements in each intervention and control group (SDE
and SDC) and the number of participants on whom the outcome was
measured in each intervention and control group (NE and NC). Net
changes were compared (that is NMES group minus exercise/control
group to give differences) by weighted mean difference (WMD) and
95% conﬁdence interval (CI). The standard deviation was calculated
for each study based on the change score method. Heterogeneity
among included studies was explored qualitatively (by comparing the
characteristics of included studies) and quantitatively (using the chi-
square test of heterogeneity and the I2 statistic). The funnel plot of stan-
dard difference ofmeanswasused as thequalitativemethod to examine
heterogeneity when more than two studies were analyzed. Where ap-
propriate, the results from included studies were combined for each
outcome to give an overall estimate of treatment effect. For all variablesNMES intervention was compared exclusively to moderate aerobic ex-
ercise intervention or usual treatment (moderate aerobic and no-
exercise control). For VO2peak, NMES intervention was compared exclu-
sively to no-exercise control. A ﬁxed-effect model meta-analysis was
used based on qualitative evaluation of the heterogeneity and the low
risk of bias. All analyses were conducted using ReviewManager Version
5.2 and comprehensive meta-analysis (Biostat Inc., Englewood, USA,
2013).4. Results
The initial search led to the identiﬁcation of 2176 studies for NMES
and HF patients from which 23 were considered as potentially relevant
and were retrieved for detailed analysis. Only 9 [14–18,20–23] were in-
cluded for all outcomes and comparison. The comparison of NMES ver-
sus moderate aerobic exercise comparison included 7 [14–18,20,22]
studies for VO2peak, 4 studies [15–18] for VO2AT, 2 studies [16,17] for
PW and 4 studies [15–18] for HRpeak. The comparison of NMES versus
no-exercise control comparison included 2 studies [21,23] for VO2peak
and NMES versus usual treatment included 9 studies [14–18,20–23]
for VO2peak, 5 studies [15–18,23] for VO2AT, 3 studies [16,17,23] for PW
and 5 studies [15–18,23] for HRpeak. Fig. 1 shows the ﬂow diagram of
studies in this review. The level of concordance between the two re-
viewers examined by Kappa statistic was 0.95 [IC 95% (0.88; 1.0)].
Fig. 3. Forest plot mean, funnel plot of standard error by standard differences in means for the comparison of neuromuscular electrical stimulation (NMES) versus usual treatment
(exercise + control) for peak oxygen consumption (VO2peak), oxygen consumption at anaerobic threshold (VO2AT), peak hear rate (HRpeak) and power workload (PW).
Table 1
Characteristics of included studies;— clinical, demographics and intervention description.
Study Quality
assessment
Outcome HF population N Age
(years)
Intervention description
Type (frequency/pulse/
time on–off and modality/
intensity)
Frequency
(days/week)
Duration
(min/day)
Protocol
(weeks)
Harris et al., 2003 [20] J-2/P-5/Q-9 VO2peak NYHA I–III LVEF b40% NMES (24)
Exercise (22)
63 ± 10
62 ± 10.8
25 Hz/ND/5–5 s
Bicycle/70% HRmax
5
5
30
30
6
6
Nuhr et al., 2004 [23] J-3/P-6/Q-10 All NYHA II–IV LVEF b35% NMES (15)
Control (17)
53 ± 7
53 ± 13
15 Hz/500 μs/2–4 s
Control
5
ND
60
ND
5
ND
Deley et al., 2005 [16] J-2/P-4/Q-11 All NYHA II–III LVEF b40% NMES (12)
Exercise (12)
56 ± 8
57 ± 6
10 Hz/200 μs/12–8 s
Bicycle, treadmill or
cycling/60–70% HRmax
5
5
60
60
5
5
Dobsak et al., 2006 [17] J-1/P-4/Q-5 All NYHA II–III LVEF b40% NMES (15)
Exercise (15)
ND
ND
10 Hz/200 μs/20–20 s
Bicycle/VO2AT
7
3
60
60
8
8
Karavidas et al., 2006 [21] J-2/P-6/Q-10 VO2peak NYHA II–III LVEF b40% NMES (16)
Control (8)
57 ± 15.3
64 ± 8.1
25 Hz/ND/5–5 s
Control
5
ND
30
ND
6
ND
Lemaitre et al., 2006 [22] J-2/P-5/Q-7 Only VO2peak NYHA II–III LVEF b35% NMES (17)
Exercise (19)
64 ± 4.7
61 ± 2.6
25 Hz/ND/5–5 s
Bicycle/70% HRmax
5
5
30
30
5
6
Deley et al., 2008 [15] J-2/P-5/Q-8 Not PW NYHA II–IV LVEF b40% NMES (22)
Exercise (22)
55 ± 10
56 ± 7
10 Hz/200 μs/12–8 s
Bicycle or treadmill/
Borg 13–15
5
5
60
60
5
5
Defteros et al., 2010 [14] J-2/P-4/Q-7 VO2peak NYHA II–III LVEF b35% NMES (31)
Exercise (31)
61 ± 2.1
61 ± 2.1
25 Hz/ND/5–5 s
Bicycle/70% HRmax
5
5
30
30
5
6
Dobsak et al., 2012 [18] J-3/P-4/Q-11 Not PW NYHA II–III LVEF b40% NMES (23)
Exercise (26)
59 ± 1.4
59 ± 2.2
10 Hz/200 μs/20–20 s
Bicycle/VO2AT
7
3
120
60
12
12
Legend: P = PEDro Scale; J = Jadad scoring; Q = Quality of Research Score Sheet; VO2peak = peak consumption of oxygen; VO2AT = consumption of oxygen at anaerobic threshold;
PW = peak workload; HRpeak = peak hear rate; NYHA = New York Heart Association; LVEF = Left-ventricular ejection fraction; NMES = neuromuscular electrical stimulation; and
ND = not described.
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Table 2
Characteristics of excluded studies.
Study Reasons for exclusion
Malek and Mark (1989) No application of any NMES
Crevenna et al. (2004) Without control group
Dobsak et al. (2006b) Without control group
Fritzsche et al. (2010) Without control group
Maillefert et al. (1998) Without control group
Quittan et al. (1999) Without control group
Wiesinger et al. (2001) Without control group
Karavidas et al. (2010) Review study
Vaquero et al. (1998) Non-HF population
Araújo et al. (2012) None of selected outcome
Karavidas et al. (2008) None of selected outcome
Quittan et al. (2001) None of selected outcome
Bittencourt et al. (2001) None of selected outcome
Eicher et al. (2004) No measure of variability
Legend: NMES = neuromuscular electrical stimulations; HF = heart failure.
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from 2003 to 2012. The 9 studies included 316 patients, 259 (81.96%)
male, with mean age ranged from 53 to 65 years. The NMES-
intervention group number of hours of treatment ranged from 12.5 to
280 (5–7 times per week, for 6–12 weeks), with the stimulation fre-
quency from 10 to 25 Hz, the pulse from 200 to 500 μs, the time on
from 2 to 20 s, the time off from 4 to 20 s, the number of contraction
from 90 to 2400 and the total energy delivered from 900 to 4800 J.
Five of the moderate aerobic exercise-intervention studies used bicycle
training, one study used bicycle or treadmill training, and one study
used bicycle, treadmill or cycling training. The moderate aerobic
exercise-intervention number of hours of treatment ranged from 15 to
36 (3–5 times per week, for 6 to 12 weeks).
The characteristics of studies excluded are presented in Table 2. Four
studies had data in different units. The VO2AT expressed in metabolic
equivalents (METs) was converted to mL kg−1 min−1 (1 MET =
3.5 mL kg−1 min−1) in one study [16]. The standard deviations were
not given in two studies [16,19], but in one study the standard devia-
tions were extracted by visual analyses while the second study was ex-
cluded because of the absence of information on variability. In another
study [18] the data of peakworkloadwere presented inW/kg and in an-
other study [13] the data of VO2peak were presented in L/min. Requests
for the above data were made via e-mail to the authors of the above
studies, but none of the authors responded which led the exclusion of
the both studies. All of the included studies were classiﬁed as RCTs
[14–18,20–23].
Heterogeneity of the included studies was low with non-signiﬁcant
chi-squared test (p b 0.05) and the I2 value ≤52%. Comparing the use
of NMES versus moderate aerobic exercise the results were favorable
to exercise for VO2peak, VO2AT and HRpeak, but PW was similar for
NMES and Exercise (Fig. 2). Comparing the use of NMES versus usual
treatment, the results were favorable to usual treatment for only HRpeak
(Fig. 3). Comparing the results of use of NMES versus no-exercise con-
trol for VO2peak, the results were not favorable to any of interventions
(Fig. 4).Fig. 4. Forest plot mean of standard error by standard differences inmeans for the comparison o
consumption (VO2peak).5. Discussion
To our knowledge, this is the ﬁrst systematic review with meta-
analysis which has assessed key CPX variables, with both prognostic
and functional signiﬁcance. We found that for HF patients NMES appar-
ently provides similar improvement in PW compared to moderate aer-
obic exercise or usual treatment, and produces beneﬁcial effects on
VO2peak, VO2AT and HRpeak but not greater than moderate aerobic
exercise.
Two previous systematic reviews in HF patients examined the effect
of functional electrical stimulation (FES) compared to exercise training
or no-exercise control on the magnitude of change in VO2peak in
mL kg−1 min−1 [24,25]. Sbruzzi et al. [24] compared the effects of FES
versus conventional aerobic exercise training for at least 5 weeks in
NYHA I–IV HF patients and observed that FES produced a beneﬁcial
effect, but not greater than exercise (−0.74 mL kg−1 min−1 [95% C.I.
−1.38 to−0.10 p b 0.02]). Similarly, Smart et al. [25] conducted a sys-
tematic reviewwithmeta-analysis inNYHA III–IV HFpatients examined
the effects of FES versus conventional aerobic cycle exercise training for
at least 2 weeks on VO2peak and also observed that FES produced
beneﬁcial effects, but not greater than exercise (−0.32mL kg−1 min−1
[95% C.I. −0.63 to −0.02, p = 0.04]). The results of the present
study are in agreement, but are slightly lower than our ﬁndings
(−0.84 mL kg−1 min−1 [95% C.I.−1.25 to−0.43 p b 0.0001]).
Our ﬁndings for VO2AT suggest that the NMES can produce effects
equal to usual treatment [0.3 mL kg−1 min−1 (95% C.I. −0.90 to 1.5,
p = 0.62)], but not greater than moderate aerobic exercise
(−0.46 mL kg−1 min−1 [95% C.I. −0.83 to 0.10, p = 0.01]). NMES
also appears to produce beneﬁcial effects in HRpeak, but also not greater
than with exercise [−5.26 bpm (95% C.I.−8.55 to−1.96, p = 0.002)]
or usual treatment [−4.96 bpm (95% C.I.−8.22 to−1.7, p = 0.003)].
The favorable changes in VO2peak, VO2AT and HRpeak from both NMES
and moderate aerobic exercise were expected since the improvement
in these variables is secondary to peripheral adaptations. Over half of
studies examining the effect of NMES and moderate aerobic exercise
on VO2peak were observed to have a clinical signiﬁcant improvement
(N1 L/kg min) [31]. Despite the fact that there does not appear to be a
clinical signiﬁcant value for increase in HRpeak and VO2AT any increase
in both is important for exercise capacity in patients with HF since
lower values are related to poor outcomes [32]. The maintenance of
the results for HRpeak even with usual treatment was unexpected and
may be related to the small sample size of the no-exercise study [21,23].
Our ﬁndings suggest that the NMES can produce effects equal
to moderate aerobic exercise [−9.91 W (95% C.I. −21.02 to 1.2,
p = 0.08)] or usual treatment [−3.12 W (95% C.I. −19.51 to 13.27,
p = 0.71)]. Greater levels of PW have been associated with improved
prognosis in patients with HF [2,4,9], thus making it a clinically relevant
measurement. The production of repeated skeletal muscle contractions
at a dose sufﬁcient to evoke visible muscle contractions induces muscle
hypertrophy [33]. Considering that the improvement in PWmay be the
primary mechanism driving the improvement in the other CPX vari-
ables, the beneﬁts on muscle strength that NMES produces appear to
positively impact global aerobic capacity. Thus, the ﬁndings of ourf neuromuscular electrical stimulation (NMES) versus no-exercise control for peak oxygen
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prognosis in all patients with HF, specially for who are unable to exer-
cise, may beneﬁt from NMES.
In fact, although the results of our study found traditional exercise
led to a greater improvement in VO2peak, VO2AT, and HRpeak, NMES was
still found to improve all of the above CPX variables, but not to the ex-
tent produced by exercise. Furthermore, our ﬁnding of similar effects
of both NMES and exercise on PW is an important ﬁnding that has not
been previously reported and thus provides a potentially greater ratio-
nale for either intervention to improve prognosis in HF.
6. Study limitations
The selection data of populationwas embracing including all severity
class (NYHA I− IV) in consequence of the lack of studies that intent to
compare individualswith different severities and the selection data of in-
tervention was in accordance with the current guidelines for aerobic ex-
ercise prescription forHF patients [10]. Even the analysis presented a low
heterogeneity, clinically the NMES protocols demonstrate a high vari-
ance of parameters inducing different muscle ﬁber type stimulation. Be-
cause of the lack of studies evaluating these prognostic variables
comparing NMES with no-exercise control group, we also chose a com-
bined analysis of both exercise and control which was deﬁned as
“usual treatment”. Despite the fact that thismethodologywas previously
used in a publishedmeta-analysis [12], these results should be cautiously
interpreted because of the heterogeneity of the interventions which can
increase the occurrence of null results. The studies included in thismeta-
analysiswere of amoderate to high quality, with principalweaknesses of
small sample size, concealment of allocation and adequacy of follow-up.
The ﬁndings of this systematic review with meta-analysis suggest
that NMES may be an important vehicle for all HF patients specially
for who are unable to perform aerobic or strength training to improve
skeletal muscle strength and endurance in order to avoid some of the
adverse manifestations of HF as well as improve exercise capacity,
prognosis and survival [10,11,34–37]. Systematic reviews and guide-
lines [27,38] strongly recommend traditional exercise-based interven-
tions for patients with HF and also identify the importance of the
improvement and long-term maintenance of functional capacity. Also,
considering the fact that not all patients adhere to exercise or are able
to perform aerobic exercise at a sufﬁcient dose to elicit training adapta-
tions, the addition of new technologies such as NMES to produce posi-
tive effects on exercise capacity and CPX results is highly important.
We also believe that further details are necessary to clarify if the syner-
gistic use of NMES and traditional exercise-based interventions is able
to produce better clinical outcomes in comparison to either [39].
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